Skip to main content
International
Ask us anything:
  • About
        • About We challenge convention so healthy can be possible
        • Our Story
          • Amneal at-a-glance
          • Our Founders
          • Our Milestones
        • Our Purpose & Commitments
        • Our Culture
          • Rise, Lead, Succeed
        • Our Leadership
          • Executive Leadership
          • Board of Directors
        • Our Locations
        • Responsibility
          • The Amneal Patient Assistance Programs
          • Product Donations
          • National & Local Philanthropy
          • Compliance and Ethics
        • Patient Community Connections
          • Our Commitment to Parkinson's
        • Awards & Recognition
  • Products
        • Products We create essential medicines
        • Our Portfolio
          • Biosciences
          • Generic Products
          • Specialty Products
          • Product Catalog
        • Quality
        • Drug Safety
          • Adverse Event Reporting
          • Medical Inquiries
          • Product Complaints
        • Operations
  • Research & Development
        • Research & Development We invest significantly in new product development
        • Generics R&D
        • Specialty R&D
          • Drug Delivery Technologies
        • Product Partnering
  • Investors
        • Investors Become an Informed Investor
  • News
  • Careers
        • Careers Help make healthy possible
        • Total Rewards
        • Search Our Career Opportunities
  • Contact
  • Customer Login
Amneal Pharmaceuticals
  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds

Home Home  >  News  >  Press Releases

  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds
Normal
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Dec 23, 2013
Federal Appeals Court Ruling Affirms Amneal’s Green Light to Market New Esomeprazole Strontium Delayed-Release Capsules
PDF format download (opens in new window)
Dec 17, 2013
Amneal Launches Esomeprazole Strontium 49.3 mg Delayed-release Capsules, a Pharmaceutical Alternative to Nexium®
PDF format download (opens in new window)
Dec 03, 2013
Impax Laboratories Announces OxyContin® Patent Challenge Settlement
Nov 27, 2013
Impax Laboratories to Present at the 25th Annual Piper Jaffray Healthcare Conference on December 3
Nov 21, 2013
Impax Laboratories Launches Generic Solaraze® (Diclofenac Sodium Gel, 3%)
Nov 07, 2013
Generic Equivalent for Loestrin® 24 Fe Coming Soon
PDF format download (opens in new window)
Nov 07, 2013
Impax Laboratories to Present at the 2013 Credit Suisse Healthcare Conference on November 14
Nov 04, 2013
Impax Laboratories Reports Third Quarter 2013 Results
Oct 30, 2013
Impax Laboratories and TOLMAR, Inc. Announce Final FDA Approval for Generic Solaraze® Gel (Diclofenac Sodium-3%)
Oct 25, 2013
Impax Laboratories Confirms Patent Challenge Relating to Generic Atelvia® Delayed-Release Tablets, 35 mg
Oct 08, 2013
Impax Laboratories Schedules Conference Call and Webcast for Third Quarter 2013 Financial Results
Sep 30, 2013
Amneal Pharmaceuticals to Acquire Four Generic Products
PDF format download (opens in new window)
Aug 13, 2013
Impax Laboratories to Present at the Canaccord Genuity Annual Growth Conference
Aug 08, 2013
Impax Laboratories Reports Second Quarter 2013 Results
Aug 02, 2013
Amneal Pharmaceuticals Announces Five New Oral Solids
PDF format download (opens in new window)
Jul 15, 2013
Impax Laboratories Launches Authorized Generic TRILIPIX® Delayed Release Capsules, 45 mg and 135 mg
Jul 09, 2013
Impax Laboratories Schedules Conference Call and Webcast for Second Quarter 2013 Financial Results
Jul 05, 2013
Mary K. Pendergast Appointed to Impax Laboratories Board of Directors
Jul 03, 2013
Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ® 4 mg and 8 mg
Jun 25, 2013
Dr. Larry Hsu, Impax Laboratories President and Chief Executive Officer, to Retire
Jun 05, 2013
Impax Laboratories Announces Reduction in Workforce
Jun 03, 2013
Impax Laboratories to Present at the Jefferies Global Healthcare Conference
May 24, 2013
Impax Laboratories to Present at the Deutsche Bank 38th Annual Health Care Conference
May 20, 2013
Impax Board of Directors Establishes Compliance Committee
May 20, 2013
Impax Laboratories to Present at the UBS Global Healthcare Conference
May 17, 2013
Impax Laboratories Launches Authorized Generic of Zomig (zolmitriptan) Tablets and Orally Disintegrating Tablets in the U.S.
May 10, 2013
Impax Laboratories to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
May 01, 2013
Impax Laboratories Reports First Quarter 2013 Results
Apr 29, 2013
Impax Pharmaceuticals and GlaxoSmithKline Terminate Their Collaboration on IPX066 (RYTARYTM)
Apr 03, 2013
Impax Laboratories Schedules Conference Call and Webcast for First Quarter 2013 Financial Results
Mar 19, 2013
Impax Pharmaceuticals Announces Presentation of RYTARYTM (IPX066) (Carbidopa and Levodopa) Extended-Release Capsules Phase III and Open-Label Extension Data at the American Academy of Neurology 2013 Annual Meeting
Mar 15, 2013
RYTARYTM (IPX066) (Carbidopa and Levodopa) Extended-Release Capsules Phase III and Open-Label Extension Data to be Presented at the American Academy of Neurology Conference
Mar 04, 2013
Impax Provides an Update on FDA Inspection of Hayward Facility
Mar 01, 2013
Impax Laboratories to Present at the Cowen & Company 33rd Annual Health Care Conference
Feb 25, 2013
Amneal Gets Approval for Generic Suboxone®
PDF format download (opens in new window)
Feb 25, 2013
Impax Laboratories Reports Fourth Quarter and Full Year 2012 Results
Feb 08, 2013
Impax and Shire Settle Litigation Concerning Supply of Authorized Generic Adderall XR®
Jan 28, 2013
Amneal Partners With Hanmi to Market Nexium® Alternative
PDF format download (opens in new window)
Jan 21, 2013
FDA Issues Complete Response Letter for RYTARY™ (Carbidopa and Levodopa) Extended-Release Capsules (IPX066) New Drug Application
Jan 17, 2013
Impax Laboratories Schedules Conference Call and Webcast for Fourth Quarter and Full Year 2012 Financial Results
Jan 04, 2013
Impax Laboratories Launches Oxymorphone Hydrochloride Extended-Release Tablets
Jan 02, 2013
Impax Laboratories to Present at the 31st Annual J.P. Morgan Healthcare Conference

Investor Faq

Get answers to important investor relation questions.

More

Investor Tools

  • Email Alerts
  • RSS Feeds
  • Email Page

IR Contact

Get answers to your investor relation questions.

More
  • Privacy Policy
  • Copyright & Legal Disclaimer
  • Web Accessibility
© Amneal Pharmaceuticals LLC.
All rights reserved.
Powered By Q4 Inc. 5.86.0.1 (opens in new window)
Back to top